Fenbendazole is an anthelmintic medication which has been available since 1970 and was originally used to treat parasitic worm infestations. Multiple scientific investigations and publications have shown that fenbendazole also helps fight cancer. These findings have led to the development of a new anti-cancer protocol in which fenbendazole is combined with dietary supplements, a healthy diet and other alternative medicine treatments. The combination of fenbendazole and other complementary treatments has been shown to effectively reduce tumor growth in a number of patients.
Although fenbendazole is a highly effective helminthic drug, its utility as an antiparasitic agent stems mainly from the fact that it binds to tubulin and disrupts the microtubule equilibrium. This action is primarily due to differences between tubulin structures in mammalian cells and in the microtubules of lower organisms.
It is therefore not surprising that fenbendazole has been used as an anticancer treatment in animal models (2-4). These studies show that the drug has potent cytotoxic and cytostatic activity against cancer cells. It also appears to inhibit the growth of tumors and their ability to metastasize, even at very low concentrations.
These results are similar to those observed in human cancer cells, in which fenbendazole has been found to be both cytostatic and cytotoxic (5-7). Because of the chemical similarities between fenbendazole and certain hypoxia-selective nitroheterocyclic cytotoxins and radiosensitizers (8-10), we investigated whether fenbendazole could enhance the radiation response of EMT6 tumors in vitro. Cultures were treated for 2 h with graded doses of fenbendazole under either aerobic or hypoxic conditions, and cell survival was measured using a colony formation assay. The survival curves shown in Figure 1 demonstrate that fenbendazole has both cytostatic and cytotoxic properties against EMT6 cells, and that the effects are largely independent of oxygen status.
In addition, we compared the effect of 2-h fenbendazole treatment on the survival of aerobic and hypoxic EMT6 tumors following local tumor irradiation. Tumor growth was monitored by determining the time to achieve four-fold volume, and these data showed that fenbendazole significantly reduced the clonogenicity of the tumors but did not affect their sensitivity to radiation.
The use of fenbendazole as an anticancer drug has been promoted by a number of unlicensed veterinarians who have posted videos on social media platforms such as TikTok and Facebook. This practice has been condemned by Sheila Singh, a professor at McMaster University who leads the Centre for Discovery in Cancer Research. The videos, featuring the story of a Canadian dog owner who claims that fenbendazole cured his cancer, have been viewed millions of times and shared widely across the internet. The safety of using this medication for humans has not been extensively studied and should only be undertaken under the supervision of a licensed veterinarian. In addition, some supplements can interact with fenbendazole, potentially decreasing its effectiveness or causing side effects. These facts have not deterred many people who want to try fenbendazole for themselves. Consequently, most of these individuals do not wait for the lengthy bureaucratic process to produce scientific data before they begin taking the drug without consulting their healthcare professional first. fenbendazole for humans